Clarivate Plc (CLVT)
Technology
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 4
Buy limit 2.24 on CLVT: post-earnings uptrend with price above every key moving average and the daily VWAP, ADX14 27.4 rising and MACD positive/expanding, but RSI14 76.50 makes the tape too extended to chase, so the entry is a GTC limit into the tested 2.24 support shelf (settled 2026-11-06 low, above the 2.19-2.22 higher lows); protective stop 2.08 (1.0xATR Change-A floor, structural swingLow 2.195 minus 0.03 buffer at 2.17), targets 2.56 and 2.80, R/R 2.00 with risk 1.00xATR versus the 0.5xATR minimum floor.
Company overview
Clarivate Plc provides information services and analytics, focusing on intellectual property management and scientific research commercialization. Its products include Web of Science, Cortellis, and Derwent, serving clients in academia, life sciences, and intellectual property sectors globally. The company is headquartered in London, UK.
Fundamental
fairClarivate is cash-generative but highly leveraged, with declining revenue and uncertain intrinsic value signals.
Clarivate is a highly levered but genuinely cash-generative subscription data franchise in mid-reset. Fiscal 2025 produced a $201 million GAAP loss dominated by non-cash intangible amortisation and impairment, yet delivered $628.5 million of operating cash flow and $365.3 million of free cash flow — a free-cash-flow yield above twenty percent on a $1.53 billion market capitalisation. The October 2026 sale of the Life Sciences & Healthcare business ($500 million cash plus a $75 million note and $25 million deferred) is being recycled into debt retirement, with November 2026 tender offers priced for up to roughly $533 million of 2028 and 2029 notes, moving pro-forma net debt from about $3.9 billion to roughly $3.3 billion and leverage from above six times toward the low fours. Offsetting that: revenue has declined for three straight years and remains soft like-for-like, GAAP profitability is still negative, the current ratio is below 1.0, leverage remains high, and the consensus analyst target of $2.13 sits below the $2.39 share price. Directors have been buying near current levels. Verdict: mixed, uncertain and execution-dependent rather than either cheap-and-safe or broken.
Sentiment
fairSentiment is forming with positive recent catalysts, but conflicting signals and a bearish analyst target cut.
Dominant driver is the announced 2026-11-03 Q3 print (EPS beat, recurring-revenue growth at its highest, partially priced) reinforced by the 2026-11-02 Microsoft Copilot trademark-data partnership, set against a bearish 2026-11-08 Goldman Sachs price-target cut to $2.30 and a near-neutral 2026-11-10 debt-tender pricing. The sentiment delta is a determinate mild improvement (baseline polarity_score ≈ +0.18 across four scored items → scoring ≈ +0.40, the latter measured on a single scored item, so low-to-moderate confidence); a moderate red-flag cap applies for conflicting catalyst signals, and no severe flag fired.
Technical
goodThe stock is in a post-earnings uptrend, supported by positive momentum and trend indicators, though overbought.
CLVT is riding a powerful post-earnings thrust: after the 2026-11-03 +29.0% gap (1.66 to 2.09 on 11.85M shares) price printed five consecutive higher closes to 2.39 and now sits above the SMA20 (1.91), SMA50 (1.84), SMA200 (2.20), EMA9 (2.16) and EMA21 (1.98), with ADX14 at 27.4 rising from ~17 in mid-October and MACD positive and expanding (line 0.15 vs signal 0.07, histogram 0.07). Momentum is overbought (RSI14 76.50, Williams %R -1.25) and price is ~30% above its SMA20, so chasing the 2.39-2.40 band carries a poor stop distance: a buy-stop at 2.42 against the structure stop 2.17 is only 1.25 R/R. The higher-quality entry is a limit into tested support at 2.24 - the settled 2026-11-06 regular-session low, sitting just above the 2.19-2.22 higher lows tagged on 2026-11-09 and 2026-11-10 - which pairs a 1.0xATR stop at 2.08 with ATR-scaled targets 2.56/2.80 for 2.00 R/R. Main caveat: the SMA50 (1.84) still sits below the SMA200 (2.20), so the primary trend is only being repaired and this is a 1-15 day momentum-continuation trade, not a trend-reversal hold. Chart quality 4: multiple bullish confirmations across trend, momentum and volume, docked one point for the extension/overbought condition and the still-inverted 50/200 stack.
You’re looking at 2026-11-10 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Technology
Not financial advice. For informational and educational purposes only.

